What Probiodrug’s Phase IIa results suggest about new biomarkers in AD
Phase II results for Probiodrug AG’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in Phase III.
A major challenge in AD drug development has been the lack of biomarkers that can be easily assessed in early trials and that correlate with clinically meaningful outcomes like improvements in cognition and/or memory.
For example, companies with programs that target the beta amyloid pathway have relied on changes in amyloid plaque levels in the brain in Phase II to support moving into large, lengthy and expensive Phase III trials.
This obviously has not panned out.
Probiodrug’s SAPHIR data for PQ912, announced June